Pfizer PFE Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $63.32B+1.4% | $62.58B-1.6% | $62.79B+3.9% | $63.83B+13.5% | $62.46B+11.6% | ||
| $16.77B-3.2% | $16.07B-10.0% | $16.7B-14.4% | $17.8B-24.3% | $17.32B-26.1% | ||
| $46.55B+3.1% | $46.51B+1.6% | $46.08B+12.6% | $46.04B+40.7% | $45.15B+38.9% | ||
| 73.5%+1.2pp | 74.3%+2.4pp | 73.4%+5.7pp | 72.1%+13.9pp | 72.3%+14.2pp | ||
| $13.72B-3.8% | $13.79B-6.4% | $13.91B-7.5% | $13.96B-7.3% | $14.27B-3.9% | ||
| $5.28B+1.7% | $4.88B-14.7% | $5B-11.0% | $5.09B-7.2% | $5.19B-3.3% | ||
| —— | —— | $9.16B— | $10.54B— | $7.4B— | ||
| $384M+175% | -$266M-850% | -$685M-70.4% | -$235M+85.3% | -$510M+66.8% | ||
| —— | —— | $9.83B— | $10.75B— | $7.88B— | ||
| $12M-25.0% | $25M+127% | $32M+245% | $24M+1,300% | $16M+176% | ||
| —— | —— | $1.72— | $1.88— | $1.38— | ||
| —— | —— | $1.72— | $1.89— | $1.39— | ||
| 22.9B+0.2% | 22.8B+0.2% | 22.8B+0.1% | 22.8B+0.3% | 22.8B+0.2% | ||
| 22.7B+0.3% | 22.7B+0.3% | 22.7B+0.3% | 22.7B+0.3% | 22.7B+0.4% | ||
| $9.49B+14.0% | $9.27B+10.5% | $8.93B+11.0% | $8.53B+9.5% | $8.33B+8.2% | ||
| $4.85B-6.6% | $4.88B-7.8% | $5B-3.7% | $5.09B+0.6% | $5.19B+5.1% | ||
| $973M-67.5% | $1.55B-35.9% | $1.7B-60.0% | $1.72B-57.7% | $3B-1.4% | ||
| $4.61B+29.0% | $4.69B+30.0% | $4.1B+20.3% | $4.41B+15.9% | $3.57B+19.0% | ||
| —— | —— | $1.72— | $1.89— | $1.39— | ||
| —— | —— | $1.72— | $1.89— | $1.39— | ||
| $0.00— | $0.00— | $0.00— | $0.00— | $0.00— | ||
| -$1.48B+36.2% | -$2.13B-1.5% | -$2.1B+41.2% | -$1.81B+43.3% | -$2.32B+29.3% | ||
| $4.61B+29.0% | $4.69B+30.0% | $4.1B+20.3% | $4.41B+15.9% | $3.57B+19.0% | ||
| $2.68B-15.4% | $2.74B-15.1% | $3.15B+8.9% | $3.16B+7.1% | $3.17B+43.1% | ||
| —— | —— | —— | —— | $219M— | ||
| -$8.53B+51.1% | -$10.9B+36.4% | -$16.01B-143% | -$18.17B— | -$17.44B— | ||
| -$3.84B— | -$1.35B— | —— | —— | —— | ||
| $12.57B-10.2% | $12.29B-3.6% | $13.66B+21.3% | $15.77B+97.0% | $13.99B— | ||
| $603M-70.9% | $470M-79.2% | $2.16B-32.6% | $2.58B-11.5% | $2.07B-44.7% | ||
| -$6.63B-42.3% | -$6.72B-53.2% | -$4.57B— | -$4.29B— | -$4.66B— | ||
| —— | —— | —— | —— | -$302M— | ||
| —— | —— | —— | —— | —— | ||
| $2.5B-9.7% | $2.63B-9.6% | $2.7B-11.0% | $2.75B-13.9% | $2.77B-20.2% | ||
| $14.1B+16.0% | $14.36B+41.7% | $16.48B+244% | $14.96B+33.3% | $12.16B-51.6% | ||
| -$386M+12.1% | -$458M+2.3% | -$429M+9.3% | -$397M+21.2% | -$439M+24.4% | ||
| —— | —— | —— | —— | —— | ||
| $1.1B-18.3% | $1.1B-30.3% | $533M-84.0% | $1.4B-33.8% | $1.35B-37.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $8.57B+76.6% | $12.95B+3,811% | ||
| $10.72B+1.8% | $10.44B-3.6% | $10.27B-3.2% | $10.32B-3.7% | $10.53B-1.3% | ||
| $901M+8.9% | $799M-8.9% | $751M-8.5% | $824M+18.1% | $827M+29.2% | ||
| $9.78B+2.1% | $9.77B+2.7% | $9.71B+2.7% | $9.64B+2.8% | $9.58B+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pfizer's revenue?
- Pfizer (PFE) generated $63.3B in revenue over the trailing twelve months, up 1.4% year over year.
- Is Pfizer profitable?
- Pfizer reported $12.1B in net income over the trailing twelve months, a 15.7% net margin.
- What is Pfizer's earnings per share?
- Pfizer's diluted EPS over the trailing twelve months is $2.12.
- Where does Pfizer's income statement data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
